| Similar Articles |
|---|
 |
The Motley Fool
January 29, 2008
Brian Lawler |
Acorda Rides the Wave Acorda Therapeutics announces positive clinical trial data on its lead multiple sclerosis drug.   |
The Motley Fool
September 25, 2007
Brian Lawler |
Acorda at a Glance Acorda Therapeutics has given astute biotech investors quite a ride over the last 12 months following positive results for their lead drug, Fampridine-SR. That drug now takes another step towards FDA approval. Investors, take note. |
The Motley Fool
June 3, 2008
Brian Orelli |
Taking a Walk With a 10-Bagger Acorda Therapeutics gets it done with phase 3 trial data on a new MS drug. |
The Motley Fool
September 26, 2006
Brian Lawler |
Four-Bagger Biotech in One Day Acorda's shares zoomed up, but potential investors should be cautious. |
BusinessWeek
April 9, 2007
Gene G. Marcial |
Acorda Tackles Multiple Sclerosis A Corda Therapeutics isn't your typical biotech. |
The Motley Fool
December 11, 2006
Brian Lawler |
Acorda Calls for 2 More Trials It'll be awhile before the FDA makes its decision on the pharma's new MS drug and the stock price settles down. |
The Motley Fool
April 29, 2011
Brian Orelli |
Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya. |
The Motley Fool
July 2, 2009
Brian Orelli |
Deal Struck, Shares Stuck Acorda Therapeutics secured a decent upfront payment to license the ex-U.S. rights to its multiple sclerosis drug, Fampridine-SR, from the perfect partner. Unfortunately, investors still smacked the stock down nearly 15% yesterday. |
The Motley Fool
January 25, 2010
Brian Orelli |
No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday. |
The Motley Fool
October 7, 2009
Robert Steyer |
Acorda's Upcoming Excitement Acorda is seeking FDA approval for a pill to improve the walking ability of multiple sclerosis patients. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
Pharmaceutical Executive
September 1, 2006 |
Finance: Good Alternatives With more ways to raise cash, biotechs with hot products can extend their independence. |
The Motley Fool
March 3, 2011
Brian Orelli |
3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year. |
The Motley Fool
February 10, 2010
Brian Orelli |
Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause. |
The Motley Fool
October 15, 2009
Robert Steyer |
Little Discord on Acorda Drug FDA advisory panel overwhelmingly backs a drug to improve the walking ability of multiple sclerosis patients. |
The Motley Fool
August 10, 2010
Brian Orelli |
Elan's Alternative to Strategic Alternatives Sometimes doing nothing is the best option. |
The Motley Fool
April 14, 2011
Arlene Weintraub |
Acorda Stock Halted as Shares Skyrocket on Patent Speculation RBC Capital Markets are suggesting good things for the company's MS drug. |
The Motley Fool
November 13, 2009
Brian Orelli |
Abbott: Brave or Stupid? Abbott Labs announces the acquisition of PanGenetics' pain drug PG110, which is still in phase 1 trials. |
The Motley Fool
April 7, 2011
Brian Orelli |
Restless No Longer XenoPort and Glaxo get a delayed FDA approval. |
The Motley Fool
May 26, 2010
Brian Orelli |
Blockbuster Drugs Aimed at Busting MS Multiple sclerosis is a large market with more entrants coming. |
The Motley Fool
November 3, 2011
Brian Orelli |
Modest Growth, Less-Than-Modest Stock Drop Dendreon's investors aren't happy. |
The Motley Fool
February 26, 2011
Brian Orelli |
FDA Applications and a Look Ahead It isn't pretty. |
The Motley Fool
October 27, 2009
Brian Orelli |
Small Market, Small Acquisition, Still a Good Move BioMarin does everything small. |
Pharmaceutical Executive
September 1, 2008 |
Place Your Bets The pharmaceutical industry is changing. Here are eight seminal events that describe how. |
The Motley Fool
August 5, 2011
Brian Orelli |
Still Want to Be the Next Dendreon? The biotech market is punished. |
